Name
Industry-Supported Product Theater (First-come basis) Discover the Impact of GEMTESA®️, An Effective OAB Treatment: A Fresh Look at OAB Management in Long-Term Care Settings
Date & Time
Friday, March 22, 2024, 12:20 PM - 1:30 PM
Description
Jonathan Shaatal, MS, RPH, FASCP
Lunch will be provided. Attendees will be admitted on a first-come basis.
GEMTESA is a β3-adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Supported by Sumitomo Pharma